BXCL501
Opioid Withdrawal
Key Facts
About BioXcel Therapeutics
BioXcel Therapeutics utilizes its proprietary AI platform to identify and develop new therapeutic applications for existing drugs, focusing on high-need neuropsychiatric and immuno-oncology indications. The company achieved its first commercial approval with IGALMI and is actively expanding its pipeline, including promising Phase 2 results for BXCL501 in opioid withdrawal. Despite commercial challenges, BioXcel continues to pursue strategic financing and clinical development to address significant unmet medical needs.
View full company profileAbout BioXcel Therapeutics
BioXcel Therapeutics utilizes its proprietary AI platform to identify and develop new therapeutic applications for existing drugs, focusing on high-need neuropsychiatric and immuno-oncology indications. The company achieved its first commercial approval with IGALMI and is actively expanding its pipeline, including promising Phase 2 results for BXCL501 in opioid withdrawal. Despite commercial challenges, BioXcel continues to pursue strategic financing and clinical development to address significant unmet medical needs.
View full company profileAbout BioXcel Therapeutics
BioXcel Therapeutics utilizes its proprietary AI platform to identify and develop new therapeutic applications for existing drugs, focusing on high-need neuropsychiatric and immuno-oncology indications. The company achieved its first commercial approval with IGALMI and is actively expanding its pipeline, including promising Phase 2 results for BXCL501 in opioid withdrawal. Despite commercial challenges, BioXcel continues to pursue strategic financing and clinical development to address significant unmet medical needs.
View full company profile